1. Introduction {#s0005}
===============

In recent years, the prognostic accuracy of ^18^F-fluorodeoxyglucose (FDG) PET concerning conversion from mild cognitive impairment (MCI) to Alzheimer\'s dementia (AD) has been discussed controversially. Some studies reported uninformative prediction accuracies of 50% ([@bb0060]) to 57% ([@bb0100]) and a recent Cochrane review ([@bb0105]) did not recommend FDG PET for clinical use for this purpose. This has been criticized ([@bb0085]), and other studies have shown that FDG PET is a significant predictor of conversion to AD ([@bb0030]; [@bb0075]; [@bb0090]).

The majority of previous FDG PET studies were limited as they used only a-priori defined region of interest (ROI)-based survival analyses ([@bb0055]; [@bb0065]; [@bb0115]) or voxel-based analyses that disregarded observation time information ([@bb0020]). In addition, previous MRI studies have shown advantages of the well-established Cox proportional hazard regression ([@bb0025]) over traditional group comparisons ([@bb0125]; [@bb0135]), when applied at voxel level.

In the present work, we aimed to use voxel-wise Cox regression to identify patterns of cerebral glucose metabolism that are significantly related to MCI to AD conversion without a-priori knowledge about typical AD patterns. The predictive value of the normalized FDG uptake within these hypometabolic clusters was evaluated and compared against other predictors in a test-dataset, using multivariate Cox regression.

To this end, we used the large imaging data collected in the scope of the Alzheimer\'s Disease Neuroimaging Initiative (ADNI, <http://adni.loni.usc.edu>), which enables a combination of voxel level analysis of FDG PET with observation time information.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

The data used in the present study is provided by the ADNI project, which is a large multi-center study with approximately 50 sites participating in the United States and Canada. It was launched in 2003 as a public-private partnership and is led by Principal Investigator Michael W. Weiner, MD. The primary goal of the ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessments could be combined to measure the progression of MCI and early AD. Comprehensive information about the ADNI project can be found at the official website.

For the present work 576 FDG PET scans of MCI patients were retrieved from the ADNI database (August 2016) with the following inclusion criteria: all patients were clinically diagnosed as MCI (DX-score 2) and had an FDG PET at baseline. A mini-mental state examination (MMSE) score of at least 24 points (n = 6 excluded), minimal follow-up of at least 6 months (n = 20 excluded, of these n = 10 had no follow-up) and no bidirectional change of DX-scores (e.g. between different ADNI phases, n = 6 excluded) were requested. The remaining 544 subjects were randomly split into equally sized cohorts A and B, see [Table 1](#t0005){ref-type="table"}.Table 1Clinical and demographic characteristics of the included Alzheimer\'s Disease Neuroimaging Initiative (ADNI) participants.Table 1Training datasetTest datasetSubjects272272Age mean (±S.D.) \[years\]74 ± 873 ± 8Sex \[M/F\]172/100163/109Education (±S.D.) \[years\]15.6 ± 415.7 ± 4MMSE score mean (±S.D.)28 ± 228 ± 2APOE ε4 positive rate49%52%Conversion rate32%34%Median follow-up (±S.D.) \[months\]48 ± 147 ± 1[^2]

2.2. FDG PET data and image preprocessing {#s0020}
-----------------------------------------

The scans were acquired at 57 different sites and across 22 scanner types. In 468 cases the images had been recorded with a dynamic protocol of 6 frames of 5-min duration, starting at 30--35 min. after injection, while the remaining 76 were scanned with a static 30-min acquisition. The reconstructed files were downloaded in their original format (DICOM, ECAT, Interfile) for meta-information and as Nifti which was ultimately used for analysis.

The preprocessing steps for the ADNI MCI scans followed recommendations for optimal statistical analysis of brain FDG PET scans in the context of MCI to AD conversion prognosis, previously described elsewhere ([@bb0075]). This processing pipeline utilized MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States) and the freely available Statistical Parametric Mapping (SPM 8) framework ([@bb0050]).

In case of dynamic scans, first a frame-by-frame motion correction to the first frame was applied and realigned frames were summed into a final static uptake image. In a second step the images were regularized into MNI space and subsequently stereotactically normalized onto an in-house FDG PET template, obtained from healthy elderly controls. Finally, the scans were proportionally scaled to brain parenchyma and a Gaussian smoothing of 12 mm full-width at half maximum (FWHM) was applied.

2.3. Region of interest derivation {#s0025}
----------------------------------

Two fundamentally different methods were applied to the training dataset in order to identify conversion-related ROIs of cerebral glucose metabolism on FDG PET. In both cases the calculations were restricted to brain parenchyma voxels.

First, a voxel-wise analysis of covariance (ANCOVA) was performed to identify voxels with significantly reduced FDG uptake in converters (n = 86) versus non-converters (n = 194) in the training dataset, adjusted for age, sex, mini-mental state examination (MMSE) score and apolipoprotein E (APOE) genotype using statistical parametric mapping (SPM) 8 software. The subsequent region of interest (ANCOVA-ROI, [Fig. 1](#f0005){ref-type="fig"}), containing all voxels with significant hypometabolism in converters compared to non-converters, was thresholded at p \< .01 (false discovery rate (FDR) corrected).Fig. 1MRI template and ROI overlays showing significant regions from the Cox model (Cox-ROI, cyan) and the analysis of covariance (ANCOVA-ROI, red). Both were derived in the training dataset (p \< .01, false discovery rate (FDR)-corrected).Fig. 1

Second, a Cox model was fit independently for each voxel within MATLAB, with normalized and subsequently z-scaled FDG uptake as predictor variable, adjusted for sex, age, MMSE score and APOE genotype. Voxels that showed a significant (FDR-corrected p \< .01) association between hypometabolism and (earlier) conversion were combined to a 'Cox-ROI' ([Fig. 1](#f0005){ref-type="fig"}). In order to match the common convention that hazard ratios above one correspond to a risk increase, the measure 'hypometabolism' was defined as a positive value. Hazard ratios below one, indicating a protective effect, were excluded for the final analysis as these seemingly hypermetabolic regions were actually due to proportional scaling (i.e. relative preserved areas like cortices).

2.4. Cox regressions in the test dataset {#s0030}
----------------------------------------

Using the ANCOVA- and Cox-ROIs derived from the training dataset, Cox regressions were carried out in the test dataset. First, the average normalized FDG uptake within both ROIs were read out for each subject in the test dataset, and used together with clinical data as covariates for five Cox models (see [Table 2](#t0010){ref-type="table"}). Multicollinearity was addressed by the usage of ridge regression. For all five Cox models, a validation of the proportional hazard assumption has been performed for all covariates by testing for multiple fractional polynomials transformation, using the *R* package *mfp* ([@bb0110]; [@bb0010]). As all covariates satisfied the proportional hazard assumption, transformations would have been only linear and were thus omitted.Table 2Variables chosen as covariates for Cox regressions in the test dataset.Table 2Model*Cox-ROIANCOVA-ROI*AgeSex*MMSE score*Education*APOE status*1----XXXXX2--X----------3X------------4--XXXXXX5X--XXXXX[^3]

In order to be able to assign a given MCI patient to a risk group, the feasibility of risk stratification was tested and illustrated using Kaplan-Meier survival curves. To this end, we calculated a prognostic index (PI) as proposed by ([@bb0095]) as follows:$${PI}\left( p \right) = {HR}_{\text{c1}} \ast c_{1}\left( p \right) + \ldots + {HR}_{\text{c6}} \ast c_{6}\left( p \right)$$with HR~ci~ = hazard ratio corresponding to c~i~ = covariate and PI = individual prognostic index for patient p.

The resulting continuous distribution of the PI was stratified into three equally-sized groups: corresponding to low, medium and high risk for conversion. For those three groups Kaplan-Meier survival curves were analyzed.

3. Results {#s0035}
==========

Using the categorical group comparison (SPM ANCOVA), significantly decreased metabolism in converters compared to non-converters in the training dataset was observed in the parietal cortex, posterior cingulate cortex and the precuneus bilaterally ([Fig. 1](#f0005){ref-type="fig"}, red regions).

Voxel-wise Cox regressions identified an association between (earlier) conversion and hypometabolism of the bilateral temporo-parietal cortex, posterior cingulate cortex/precuneus, and frontal cortex in the training dataset ([Fig. 1](#f0005){ref-type="fig"}, cyan regions; see [Fig. 2](#f0010){ref-type="fig"} for topography of voxel-wise HR). As shown in [Fig. 1](#f0005){ref-type="fig"}, regions identified by voxel-wise Cox regressions (66 cm^3^) considerably extended beyond those identified by SPM ANCOVA (6 cm^3^).Fig. 2Surface projection of the hazard ratios from the voxel-wise Cox model in the training dataset. Hazard ratios above one correspond to one-unit decrease in the normalized and z-scaled ^18^F-fluorodeoxyglucose (FDG) uptake.Fig. 2

For the test dataset, model 1 yielded APOE (HR = 1.6 \[95% C.I.: 1.2--2.1\], p \< .001) and MMSE (HR = 1.24 \[95% C.I.: 1.1--1.4\], p \< .001) as independent predictors with an Akaike information criterion ([@bb0005]) (AIC) of 883 (Wald test (WT) p \< .001).

Model 2, using only the normalized FDG uptake within the ANCOVA-ROI, also significantly predicted MCI to AD conversion with a HR = 1.35 \[95% C.I.: 1.2--1.5\] and AIC = 901 (WT: p \< .001).

Model 3 (Cox-ROI-only) yielded comparable results with a HR = 1.29 \[95% C.I.: 1.2--1.4\] and AIC = 904 (WT: p \< .001).

Model 4, consisting of the clinical variables and normalized FDG uptake from the ANCOVA-ROI yielded all three as independent predictors, with an AIC of 875 (WT: p \< .001): FDG uptake from ANCOVA-ROI (HR = 1.2 \[95% C.I.: 1.1--1.4\], p \< .001), APOE (HR = 1.6 \[95% C.I.: 1.2--2.1\], p \< .001) and MMSE (HR = 1.2 \[95% C.I.: 1.1--1.4\], p \< .003), see also [Fig. 3](#f0015){ref-type="fig"}.Fig. 3Resulting hazard ratios for models 4 (left) and 5 (right). All covariates have been transformed to z-scores, except for sex and APOE status which are dichotomous. The MMSE has been multiplied by −1 to yield a positive HR, in order to increase comparability.Fig. 3

Comparable results were found for model 5, with the normalized FDG uptake, APOE and MMSE as independent predictors (HR = 1.2 \[95% C.I.: 1.1--1.3\], HR = 1.6 \[95% C.I.: 1.2--2.1\], HR = 1.2 \[95% C.I.: 1.1--1.4\], respectively; all p \< .001) with an AIC = 878 (WT: p \< .001), see also [Fig. 3](#f0015){ref-type="fig"}.

The clinical-only model (1) was significantly improved by adding normalized FDG uptake in the ANCOVA-ROI in model 4 (relative likelihood (1) to (4): L = 0.018). Similarly, it was improved by adding normalized FDG uptake in the Cox-ROI in model 5 (at trend level, relative likelihood (1) to (5): L = 0.08).

A change between model 4 and 5 was not beneficial: relative likelihood (4) vs (5): L = 0.22.

Finally, changing from either model 2 or 3 towards model 4 or 5 yielded a strong improvement, all relative Likelihood tests yielded L \< 0.001.

The prognostic value of the Cox models in the test dataset was evaluated by comparing survival curves for the three risk groups. A comparison of [Fig. 4](#f0020){ref-type="fig"} (model 1, clinical-only) and [Fig. 5](#f0025){ref-type="fig"} (model 4, clinical plus normalized FDG uptake on ANCOVA-ROI) showed that the inclusion of imaging data improved the separation in between the different risk groups. As indicated by median conversion times, separation of the high- from the medium-risk group was worse in model 1 (48 \[95% C.I.: 35-n/a\] months vs. 60 \[95% C.I.: 51-n/a\] months), than in model 4 (36 \[95% C.I.: 27--49\] months vs. 85 \[95% C.I.: 60-n/a\] months). Likewise, the hazard ratios of the high-risk groups were 8.1 compared to 4.9 but 3.2 and 3.4 for the median-risk group (with low-risk group as reference, see [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}), respectively. After about 60 months, the number of subjects left is too small to draw conclusions. Very comparable results were found for model 5 (clinical plus normalized FDG uptake on Cox-ROI), see [Fig. 6](#f0030){ref-type="fig"}.Fig. 4Survival curves for model 1 including only clinical covariates sex, age, MMSE score and APOE genotype. Three risk groups were defined corresponding to the lower, middle and upper thirds of subjects in the prognostic index (PI) distribution. With the low-risk group defined as reference, the hazard ratios are 3.4 \[95% C.I.: 1.8--6.4, p \< .001\] and 4.9 \[95% C.I.: 2.6--9.1, p \< .001\] for the medium- and high-risk group, respectively.Fig. 4Fig. 5Survival curves for model 4 including clinical covariates and normalized FDG uptake values from within the ANCOVA-ROI. Three risk groups were defined corresponding to the lower, middle and upper thirds of subjects in the PI distribution. With the low-risk group defined as reference, the hazard ratios are 3.2 \[95% C.I.: 1.6--6.3, p \< .001\] and 8.1 \[95% C.I.: 4.2--15.6, p \< .001\] for the medium- and high-risk group, respectively.Fig. 5Fig. 6Survival curves for model 5 including clinical covariates and normalized FDG uptake from the Cox-ROI. Three risk groups were defined corresponding to the lower, middle and upper thirds of subjects in the PI distribution. With the low-risk group defined as reference, the hazard ratios are 3.6 \[95% C.I.: 1.8--7.1, p \< .001\] and 7.7 \[95% C.I.: 4.0--14.8, p \< .001\] for the medium- and high-risk group, respectively.Fig. 6

The survival curves for models 2 and 3 can also be found in the supplementary material, see [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}. Both show a very good separation of the high-risk group, whereas the low- and medium-risk groups were less satisfactorily separated.Fig. 7Survival curves for model 2 including only normalized FDG uptake within the ANCOVA-ROI. Three risk groups were defined corresponding to the lower, middle and upper thirds of subjects in the PI distribution. With the low-risk group defined as reference, the hazard ratios are 2.2 \[95% C.I.: 1.1--4.4, p \< .001\] and 6.8 \[95% C.I.: 3.7--13, p \< .001\] for the medium- and high-risk group, respectively.Fig. 7Fig. 8Survival curves for model 3 with only normalized FDG uptake within the Cox-ROI. Three risk groups were defined corresponding to the lower, middle and upper thirds of subjects in the PI distribution. With the low-risk group defined as reference, the hazard ratios are 2 \[95% C.I.: 1--4, p \< .001\] and 9.2 \[95% C.I.: 4.8--17.7, p \< .001\] for the medium- and high-risk group, respectively.Fig. 8

Finally, [Table 3](#t0015){ref-type="table"} shows the annual conversion rates for all models and risk groups after 1, 3 and 5 years.Table 3Conversion rates \[%\] after 1, 3 and 5 years for all models and risk groups.Table 3Risk groupLowMediumHighTime \[years\]135135135Model13.58.613.17.933.352.815.841.963.224.69.919.74.622.229.418.250.278.434.69.615.23.417.229.619.356.189.143.49.919.75.722.229.418.050.278.453.46.010.26.927.346.416.750.276.0

4. Discussion {#s0040}
=============

In the present study, voxel-wise Cox regression identified brain regions for which decreased metabolism was significantly associated with MCI to AD conversion. This pattern included the hypometabolic clusters derived from the reference method (ANCOVA SPM), but was more widespread and (at the same selected significance threshold) also involved the frontal cortex. The identified conversion-related brain regions ([Fig. 1](#f0005){ref-type="fig"}), including frontal cortex, coincided with the well-established regions of cerebral hypometabolism in MCI ([@bb0035]) and AD ([@bb0015]; [@bb0070]). Although the Cox-ROI was noticeably larger than the ANCOVA-ROI, both covered similar brain regions and the normalized FDG uptake within the two regions was highly correlated. Consequently, the Cox model pairs 2 and 3 as well as 4 and 5 in the test dataset led to comparable results, respectively. Apparently, the classical group comparison already identified the most relevant areas, and the additional information contained in the slightly larger Cox-ROI had no added value concerning the prediction of conversion to AD. Therefore, the inclusion of observation time information via voxel-wise Cox regression, used to identify the Cox-ROI, was not superior to traditional group contrasts for identification of conversion-related regions.

Of note, the prognosis of conversion to AD by APOE genotype and MMSE score was significantly improved when imaging information (normalized FDG uptake based on either method) was included.

Identification of conversion-related hypometabolism in frontal regions might indicate greater sensitivity of the Cox regression method. However, notably the predictive power of models including the Cox regression-derived FDG uptake (and hence frontal metabolism) was not superior to those including FDG uptake from conventionally derived regions (excluding frontal regions), which might also indicate that frontal regions play only a minor role in conversion to AD.

The applied stratification into risk groups based on the calculated prognostic index has the advantage of individual predictions of conversion probability within arbitrarily chosen time frames (e.g., 1, 3, or 5 years, see [Table 3](#t0015){ref-type="table"}). This might be of value for patient counseling in clinical routine.

Limitations for the Cox regression method, as applied in both datasets, include the fact that the set of chosen predictor variables was not comprehensive: For instance, it did not include information about beta-amyloid or tau from PET imaging, cerebrospinal fluid (CSF), or structural information from MRI. Also, more detailed cognitive performance data (e.g. Montreal Cognitive Assessment, which has not been available for about half of the patients in this study) might be important covariates. In addition, comorbid diseases like vascular pathologies may both obscure and mimic an AD-pathology.

However, the current study aimed at testing the method of voxel-wise Cox regressions and hence results were only compared to those of conventional group contrasts and adjusted for commonly used clinical covariates.

Concerning the predictive value of FDG PET in the context of MCI to AD conversion, the literature shows a large heterogeneity. While the current study and [@bb0075] found a significant predictive value for FDG PET within the ADNI data, others did not ([@bb0100]; [@bb0120]). Beyond differences in employed methods, reasons for this obvious discrepancy might be different subsets of the constantly growing ADNI sample, based on the time of download and inclusion criteria. This is apparent when comparing annual conversion rates of different ADNI samples: while the current study used a dataset with an annual conversion rate of 8.7%, in ([@bb0065]) it was 17.2%, in ([@bb0120]) even 20% and ([@bb0080], [@bb0075]) report about 9.5% and 6.3%, respectively. It has been pointed out that the ADNI database does not represent the general population ([@bb0130]). Therefore, the predictive value of FDG PET that we found might not necessarily apply to other samples tested. In line with this, smaller studies ([@bb0060]; [@bb0120]), ([@bb0040]) did not support this, although a meta-analysis of ([@bb0045]) showed a clear advantage of FDG PET for conversion prediction over other modalities.

5. Conclusions {#s0045}
==============

We demonstrated that voxel-wise Cox regression can be used to identify MCI to AD conversion-related patterns of cerebral glucose metabolism, but does not outperform classical group contrasts in this regard. With imaging information from these patterns on FDG PET, the prediction of conversion to AD was improved in the ADNI dataset.

The following are the supplementary data related to this article.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0005}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: Apolipoprotein E (APOE) ε4 status is defined as positive if at least one epsilon 4 allele is present. The median follow-up was calculated as the reversed Kaplan-Meier estimate. MMSE = mini-mental score examination.

[^3]: The variables sex (male = 1, female = 0) and APOE status (positive if at least one epsilon 4 allele present) are dichotomous. (ROI = region of interest, ANCOVA = analysis of covariance).
